Figure 12:
Surface representation of JAK3. a): An overlay of the designed inhibitors 39 (red), 45(green), 52 (blue), and 57 (orange) in the binding cavity of JAK3. b): Tofacitinib in the binding cavity of JAK3.
Surface representation of JAK3. a): An overlay of the designed inhibitors 39 (red), 45(green), 52 (blue), and 57 (orange) in the binding cavity of JAK3. b): Tofacitinib in the binding cavity of JAK3.